Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 12/20 | 0.59 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GPR6 | P46095 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771433 | 0.93 | GCK (0.60) | GCKKMT2A | |
| SCHEMBL184389 | 0.92 | GCK (0.61) | GCKALDH1A1KMT2AMEN1 | |
| SCHEMBL3775046 | 0.86 | GCK (0.62) | GCK | |
| SCHEMBL185103 | 0.84 | GCK (0.63) | GCK | |
| SCHEMBL3766320 | 0.83 | GCK (0.56) | GCK | |
| SCHEMBL11997719 | 0.82 | GCK (0.58) | GCKALDH1A1KMT2AMEN1 | |
| SCHEMBL3773195 | 0.82 | GCK (0.73) | GCKALDH1A1KMT2A | |
| SCHEMBL2658351 | 0.82 | GCK (0.62) | GCK | |
| SCHEMBL11972473 | 0.82 | GCK (0.63) | GCK | |
| SCHEMBL184524 | 0.81 | GCK (0.61) | GCKALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501955-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2013-08-06 | — | — | US | claimed |
| EP-2402327-A1 | Acetamide compounds as glucokinase activators, their process and medicinal applications | Advinus Therapeutics Private Limited (IN) | 2012-01-04 | — | — | EP | claimed |
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-12-09 | — | — | US | claimed |
| EP-2402327-B1 | Acetamide compounds as glucokinase activators, their process and medicinal applications | IMPETIS BIOSCIENCES LTD (IN) | 2018-03-07 | — | — | EP | disclosed |
| US-8501955-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2013-08-06 | — | — | US | disclosed |
| EP-2402327-A1 | Acetamide compounds as glucokinase activators, their process and medicinal applications | Advinus Therapeutics Private Limited (IN) | 2012-01-04 | — | — | EP | disclosed |
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | GCK, GCKR, ALDOA | GCK 1/4885APOBEC3A 1818/4885APOBEC3G 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.